AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.
New cancer therapies may help fund dividend growth.
AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.
Overview
AbbVie (NYSE: ABBV) boasts a pretty attractive dividend at more than 3%.
That's significantly higher than many other blue-chip healthcare stocks, including Eli Lilly (NYSE: LLY), Johnson & Johnson (NYSE: JNJ), and Amgen (NASDAQ: AMGN), all of which yield dividends of roughly 2% or less.
Details
But dividends don't increase just because management wants them to. They rise because the business generates enough cash to support them.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
